Glenmark to market generic Abraxane from Lubrizol LifeSciences

abraxaneGlenmark Pharmaceuticals, Inc., USA said it has entered into a strategic Development, License and Commercialization Agreement with Particle Sciences, Inc. to develop and market a generic version of Celgene’s Abraxane, used for cancer treatment.

As per the terms of the agreement, Glenmark has obtained global exclusive marketing and distribution rights of the product upon commercialization.

Particle Sciences, part of Lubrizol LifeSciences, is an integrated provider of drug development services and is based in Bethlehem, Pennsylvania.

Abraxane marketed globally by Celgene has reported sales of USD 967 million world-wide and USD 654 million in the USA in the calendar year 2015. It is paclitaxel protein (albumin)-bound particles for injectable suspension.

¨Particle Sciences will develop this product exclusively for Glenmark, and shall receive certain milestone payments during various stages of the product’s development from Glenmark, including royalties on sales. Development of the product has been initiated for the USA market and Glenmark intends to file the ANDA in FY19. The product will be subsequently filed in other key markets across the globe,¨ the Indian company said.

“The partnership is a significant development in Glenmark’s complex generics strategy and we are pleased to
collaborate with Particle Sciences given their strong technical capabilities and understanding of particulate
injection products. This is a challenging product to develop and we expect it to remain a limited competition
opportunity,” said Robert Matsuk, President – North America and Global API, Glenmark Pharmaceuticals
Limited.

Abraxane is used for the treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. It can also be used for non-small cell lung cancer (NSCLC), as first-line treatment and in pancreatic cancer treatment.

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization
headquartered at Mumbai, India.



Govt of India starts crack down on low-quality medicine makers The government of India has started conducting inspections at drug manufacturing units across the country to prevent the production of low-quality drugs and medicines in India.Typically, inspections are conducted by state authorities, while central agencies largely confine themselves to checking quality of final products put up on store shelves.H...
SUSPENSE: Will Flipkart sell OnePlus 3 or not? With minutes remaining for the planned 4 PM flash sale of heavily discounted OnePlus 3 phones, the suspense over whether Flipkart will actually go ahead with the sale or not has hit a peak.On social media, there are reports that Flipkart will actually go ahead and conduct a sale anyway.However, there are no signs of the impending flash-sale on the re...
Will OnePlus 3 from Flipkart get warranty support from manufacturer? OnePlus 3, arguably the most successful premium phone of 2016 in India, may not get warranty support from the manufacturer if purchased from Flipkart, going by a statement by the company.The company issued a statement that seemed to suggest that Flipkart's sale of the model is not authorized by the company."We have an exclusive partnership with A...
Flipkart to sell OnePlus 3 with huge discount; Company says not done! Flipkart, the homegrown ecommerce giant, has listed OnePlus 3 as one of the prominent mobile deals being offered under its 'Big Shopping Days' sale to be held from Saturday, Dec 17 onwards.It has also put up a 'coming soon' page for the sought-after smartphone model.However, OnePlus has an agreement with Amazon India that it will only sell its ph...
Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been terminated.The total investment will be euro 16.875 million, which comes to about...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS primarily develops, manufactures and markets products across various therapeuti...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta tablets of Boehringer Ingelheim Pharmaceuticals, Inc.An Abbreviated New Drug ...
Lupin launches injectable iron formulations in India Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.The product is currently marketed in 33 countries, including 21 European Union coun...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, r...
Youtuber blows whistle on paid gadget news and reviews in India Youtuber Gaurav Chaudhary, who goes by the name of Technical Guruji, has set off a minor storm in the gadget reviewer circles by accusing many of his peers of passing on paid reviews for the real thing.Chaudhary dons the mantle of the whistleblower and warns his fellow reviewers and Youtubers not to cheat their audience by posting paid reviews."Pleas...
Sun Pharma to get dengue vaccine technology from ICGEB Pharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being developed to commercialize in Indian and international markets.A serotype is a...
Aarti Industries to return Rs 96 cr to shareholders via buyback Speciality Chemicals company Aarti Industries Ltd said it will buy back12 lakh equity shares at Rs 800 each, aggregating to Rs 96 cr.The company´s Board of Directors approved the equity shares -- representing up to 1.44% of the company's base."The public announcement setting out the process, timelines and other requisite detail will be released in du...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol Capsules are therapeutically equivalent to the reference l...
India overdependent on China for medicines – study India may have emerged as a key supplier of generic and affordable medicine for the world market, but it has an "overwhelming dependence" on China for the raw material required to produce these drugs, industry association Assocham said.Indian companies depend on China to supply them with the main raw material in drug making -- known as Active Pharmaceuti...
Lupin licenses taste-masking technology from Monosol for paediatric tablets Pharma Major Lupin Ltd. said its US subsidiary, Lupin Pharmaceutical Inc., has agreed to license technology from Monosol Rx to develop multiple paediatric-focused products.Lupin would develop the pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery technology.MonoSol Rx’s PharmFilm technology is a drug delivery platform tha...